You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost.
In a study involving 250 military veterans, researchers have reported identifying and testing gene expression biomarkers whose levels rise with human stress.
Researchers developing the gene expression-based test say it could bring objectivity to a subjective diagnosis and result in more targeted treatments.
NX Prenatal and Indiana University School of Medicine are collaborating to develop exosome blood tests for preterm birth risk and preeclampsia.
The ASPIRE algorithm uses cell phenotype information from bone marrow samples to predict which patients will relapse and which will go into remission.
Roche, Eli Lilly, and others aim to elucidate differences in T2D patients in order to develop better diagnostic tools and new treatments.